Abstract. Atherosclerotic cardiovascular disease and acute myocardial infarction are the leading causes of mortality worldwide, and apoptosis is the major pathway of cardiomyocyte death under hypoxic conditions. Although studies have reported changes in the expression of certain pro-apoptotic and anti-apoptotic genes in hypoxic cardiomyocytes, genetic regulations are complex in human cardiomyocytes and there is much that remains to be fully elucidated. The present study aimed to identify differentially expressed genes in hypoxic human AC16 cardiomyocytes using next-generation sequencing and bioinformatics. A total of 24 genes (15 upregulated and 9 downregulated) with potential miRNA-mRNA interactions were identified in the miRmap database. Utilising the Gene Expression Omnibus database of cardiac microvascular endothelial cells, tensin 1, B-cell lymphoma 2-interacting protein 3 like, and stanniocalcin 1 were found to be upregulated, and transferrin receptor and methyltransferase like 7A were found to be downregulated in response to hypoxia. Considering the results from miRmap, TargetScan and miRDB together, two potential miRNA-mRNA interactions were identified: hsa-miRNA (miR)-129-5p/CDC42EP3 and hsa-miR-330-3p/HELZ. These findings contribute important insights into possible novel diagnostic or therapeutic strategies for targeting cardiomyocytes under acute hypoxic stress in conditions, including acute myocardial infarction. The results of the present study also introduce an important novel approach in investigating acute hypoxic pathophysiology.

Introduction

Atherosclerotic cardiovascular disease is the leading cause of mortality worldwide (1,2). The cardiomyocytes (CMs) in patients with acute myocardial infarction (AMI) undergo cell death, alteration of cell cycle, and abrupt mitochondrial oxidative metabolism in either ischemic or hypoxic conditions (3-5). Therefore, antiplatelet agents, anticoagulation agents, and emergent coronary revascularization are often used to treat patients with acute coronary syndrome (6).

Apoptotic cell death is important in myocardial damage following AMI, which may lead to malignant arrhythmia, heart failure and cardiac death (7,8). During hypoxia and reoxygenation injury, CMs exhibit typical morphological characteristics of apoptotic nuclei, including membrane blebs, myofibillary disarrangement, chromatin condensation, and peripheral margination of mitochondria (3). Increased myocardial apoptosis has also been found in autopsies of patients who have succumbed to AMI and multi-vessel coronary artery diseases (9,10). Furthermore, changes in several pro-apoptotic and anti-apoptotic mediators have been noted in ischemic or hypoxic CMs in vivo, in isolated animal hearts, and in humans (5,7,8,11,12).

Unlike traditional Sanger sequencing technology, next-generation sequencing (NGS) provides rapid analyses of large quantities of genomic information, including DNAs, mRNAs, microRNAs (miRNAs), and non-coding RNAs (13,14). Using NGS in combination with bioinformatics...
analyses, whole exon sequencing has been performed in previous studies to identify a wide spectrum of genetic mutations in several scientific fields (13,14). NGS has also been used to identify novel genetic regulations in basic and clinical research (15,16), and it has been used in the genetic diagnosis of congenital heart diseases and inherited cardiac dysrhythmia (16,17).

Although several studies have investigated the signaling pathways and cellular responses of CMs in ischemic or hypoxic conditions, the regulation of genetic expression with regard to hypoxia-related apoptosis is complex and remains to be fully elucidated (18-20). Therefore, the present study was designed to perform a comprehensive investigation of various genetic expression changes in hypoxic human cardiomyocytes using NGS and bioinformatic analyses.

Materials and methods

Cell culture. The AC16 human cardiomyocyte cell line, purchased from EMD Millipore (Billerica, MA, USA), was cultured following standard manufacturer protocol. The cells (1x10^6 cells/well) were seeded in 10% FBS (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and DMEM/F-12 medium (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and allowed to grow overnight. The AC16 CMs were then incubated in either a normoxic condition (37˚C, 20% O_2 and 5% CO_2) or hypoxic condition (37˚C, 1% O_2 and 5% CO_2) for 24 h. The hypoxic condition was maintained in a physiological oxygen workstation (InvivO2 400; Baker Ruskinn, Sanford, ME, USA).

Flow cytometry and detection of apoptosis. The cells were analyzed using an Annexin V-FITC Early Apoptosis Detection kit (Cell Signaling Technology, Inc., Danvers, MA, USA) and a BD Accuri C6 Plus flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) as previously reported (21).

RNA sequencing. Total RNAs from the normoxic and hypoxic AC16 CMs were extracted with TRIzol reagent (Invitrogen, Thermo Fisher Scientific, Inc.) following the manufacturer's standard protocol. The purified RNA was measured at OD_260nm with an ND-1000 spectrophotometer (Nanodrop Technologies; Thermo Fisher Scientific, Inc., Waltham, DE, USA) and qualitatively analyzed with an RNA 6000 LabChip kit (Agilent Technologies, Inc., Santa Clara, CA, USA) and the Bioanalyzer 2100 (Agilent Technologies, Inc.).

Library preparation and deep sequencing were performed according to the manufacturer's protocol (Illumina, Welgene Biotechnology Company, Taipei, Taiwan), as described in our previous reports (15,22). For small RNA sequencing, following reverse transcription of total RNA, cDNA with sizes indicating 18-40-nucleotide RNA fragments (140-155 nucleotides in length with both adapters) was extracted and sequenced on the Illumina instrument (75 single-end cycles). Following trimming or removing low-quality data using Trimmomatic (version 0.36) (23), the qualified reads were analyzed using miRDeep2 software (version 2.0.0.8) (24) and the human genome from the University of California Santa Cruz (UCSC) database (https://genome.ucsc.edu/). The miRNAs with low levels [<1 normalized read per million (rpm)] in both hypoxic and normoxic cells were excluded. For transcriptome sequencing, the library constructed with the SureSelect Strand Specific RNA Library Preparation kit (Agilent Technologies, Inc.) was sequenced with the TruSeq SBS kit on the Solexa platform (Illumina NextSeq 500; 75 cycles, single-end). Following trimming or removing low-quality data using Trimmomatic (23), the qualified reads were analyzed using Cufflinks (25) and the Ensembl database (https://asia.ensembl.
The genes with low expression levels (<0.3 fragment per kilobase of transcript per million mapped reads) in both hypoxic and normoxic cells were excluded. miRNA database analyses. The miRmap is a web database used to predict putative genes targeted by candidate miRNAs and is available from http://cegg.unige.ch/mirmap (26). In the present study, a search was performed for putative targeted miRNAs from human species and miRmap scores >99.0. A search was also performed for potential miRNA interactions in the miRmap, TargetScan (http://www.targetscan.org/vert_71/) and miRdB (http://www.mirdb.org/) databases.

Ingenuity® Pathway Analysis (IPA). IPA software (Ingenuity Systems, Redwood City, CA, USA) integrates numerous results and performs multiple analyses providing a comprehensive interpretation of a large quantity of experimental data. In the present study, IPA analysis was performed for the network analyses of candidate genes.

Gene expression omnibus (GEO) database analysis. The GEO database (https://www.ncbi.nlm.nih.gov/geo/) is a useful web database containing raw gene expression data from microarray studies and NGS. The present study used a GEO array (GEO accession: G0S3483) investigating the gene responses to hypoxia in primary human pulmonary microvascular endothelial cells and cardiac microvascular endothelial cells (27). Data were collected from the cardiac microvascular endothelial cells under normoxia or hypoxia (1% O₂, 5% CO₂, and 94% N₂) over various durations (3, 24 and 48 h). The raw data extracted from the GEO database were re-plotted and statistically analyzed using analysis of variance (ANOVA) followed by Dunnett’s test using GraphPad Prism® 7 software (GraphPad Software, Inc., La Jolla, CA, USA).

Database for Annotation, Visualization and Integrated Discovery (DAVID) analysis. The DAVID (https://david.ncifcrf.gov/) database (28) is a useful tool for gene functional classification. It integrates data from multiple functional annotation databases, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. A list of genes of interest is classified by clustering of related biological functions, signaling pathways, or diseases by calculating the similarity of global annotation profiles using an agglomeration algorithm method. The functions of differentially expressed genes were analyzed following methods used in our previous studies (15,22).

Statistical analysis. The expression levels of the genes were compared between cells treated with hypoxia for different lengths of time (3, 24 and 48 h) and normoxic cells using ANOVA, followed by Dunnett’s test. P<0.05 (two-tailed) was considered to indicate a statistically significant difference.

**Results**

**Gene expression profiling and miRNA changes in hypoxic AC16 CMs.** As shown in Fig. 1A, RNAs were extracted from the cells and sent for NGS followed by bioinformatics analyses. The AC16 CMs incubated under hypoxic conditions exhibited increased apoptosis compared with the cells incubated under normoxic conditions (Fig. 1B).

A volcano plot of differentially upregulated (right panel) and downregulated (left panel) gene expression in hypoxic, vs. normoxic AC16 CMs is shown in Fig. 2A. Genes with -log₁₀ (P-value) >1.3 and ≥2-fold changes (Fig. 2B) were selected for further analyses. The small RNA-sequencing data generated with NGS were analyzed to identify potentially significant changes in miRNA profiles in the AC16
### Table I. miRNAs with significant change in hypoxic, vs. normoxic AC16 CMs.

| miRNA                        | Precursor | AC16 CMs hypoxia seq (norm) | AC16 CMs normoxia seq (norm) | Fold change | Up/down |
|------------------------------|-----------|-----------------------------|-------------------------------|-------------|---------|
| hsa-miR-10b-3p               | hsa-mir-10b | 2.81                        | 1.03                          | 2.73        | Up      |
| hsa-miR-1276                 | hsa-mir-1276 | 4.84                        | 1.84                          | 2.63        | Up      |
| hsa-miR-142-5p               | hsa-mir-142 | 6.08                        | 2.18                          | 2.79        | Up      |
| hsa-miR-181b-2-3p            | hsa-mir-181b-2 | 8.33                        | 3.33                          | 2.50        | Up      |
| hsa-miR-210-3p               | hsa-mir-210 | 392.50                      | 122.50                        | 3.20        | Up      |
| hsa-miR-210-5p               | hsa-mir-210 | 23.52                       | 8.49                          | 2.77        | Up      |
| hsa-miR-212-5p               | hsa-mir-212 | 6.19                        | 1.95                          | 3.17        | Up      |
| hsa-miR-224-3p               | hsa-mir-224 | 4.61                        | 1.15                          | 4.01        | Up      |
| hsa-miR-26a-2-3p             | hsa-mir-26a-2 | 7.43                        | 2.75                          | 2.70        | Up      |
| hsa-miR-299-5p               | hsa-mir-299 | 27.57                       | 10.09                         | 2.73        | Up      |
| hsa-miR-3200-3p              | hsa-mir-3200 | 10.01                       | 3.67                          | 2.73        | Up      |
| hsa-miR-330-3p               | hsa-mir-330 | 9.79                        | 4.70                          | 2.08        | Up      |
| hsa-miR-33a-3p               | hsa-mir-33a | 3.15                        | 1.26                          | 2.50        | Up      |
| hsa-miR-34b-3p               | hsa-mir-34b | 13.39                       | 5.28                          | 2.54        | Up      |
| hsa-miR-365b-5p              | hsa-mir-365b | 3.60                        | 1.15                          | 3.13        | Up      |
| hsa-miR-3944-5p              | hsa-mir-3944 | 2.48                        | 1.15                          | 2.16        | Up      |
| hsa-miR-454-5p               | hsa-mir-454 | 14.40                       | 5.73                          | 2.51        | Up      |
| hsa-miR-485-3p               | hsa-mir-485 | 22.84                       | 5.51                          | 4.15        | Up      |
| hsa-miR-486-3p               | hsa-mir-486-1 | 8.78                        | 2.64                          | 3.33        | Up      |
| hsa-miR-486-3p               | hsa-mir-486-2 | 8.89                        | 2.29                          | 3.88        | Up      |
| hsa-miR-494-3p               | hsa-mir-494 | 18.00                       | 8.83                          | 2.04        | Up      |
| hsa-miR-548e-3p              | hsa-mir-548e | 6.86                        | 3.21                          | 2.14        | Up      |
| hsa-miR-550a-3p              | hsa-mir-550a-1 | 2.48                        | 1.03                          | 2.41        | Up      |
| hsa-miR-550a-3p              | hsa-mir-550a-2 | 2.48                        | 1.03                          | 2.41        | Up      |
| hsa-miR-550a-3p              | hsa-mir-550a-3 | 2.48                        | 1.03                          | 2.41        | Up      |
| hsa-miR-5690                 | hsa-mir-5690 | 5.51                        | 2.41                          | 2.29        | Up      |
| hsa-miR-582-3p               | hsa-mir-582 | 9.45                        | 3.67                          | 2.57        | Up      |
| hsa-miR-590-3p               | hsa-mir-590 | 15.42                       | 7.34                          | 2.10        | Up      |
| hsa-miR-641                  | hsa-mir-641 | 8.21                        | 3.90                          | 2.11        | Up      |
| hsa-miR-766-3p               | hsa-mir-766 | 10.69                       | 5.05                          | 2.12        | Up      |
| hsa-miR-92b-5p               | hsa-mir-92b | 11.59                       | 5.51                          | 2.10        | Up      |
| hsa-miR-98-3p                | hsa-mir-98  | 8.78                        | 4.36                          | 2.01        | Up      |
| hsa-miR-1249-3p              | hsa-mir-1249 | 2.48                        | 5.28                          | -2.13       | Down    |
| hsa-miR-1262                 | hsa-mir-1262 | 1.35                        | 3.56                          | -2.64       | Down    |
| hsa-miR-1292-5p              | hsa-mir-1292 | 1.24                        | 2.52                          | -2.03       | Down    |
| hsa-miR-1303                 | hsa-mir-1303 | 2.59                        | 5.51                          | -2.13       | Down    |
| hsa-miR-1306-5p              | hsa-mir-1306 | 1.69                        | 4.01                          | -2.37       | Down    |
| hsa-miR-134-3p               | hsa-mir-134 | 1.58                        | 3.44                          | -2.18       | Down    |
| hsa-miR-1908-3p              | hsa-mir-1908 | 1.01                        | 2.29                          | -2.27       | Down    |
| hsa-miR-23a-5p               | hsa-mir-23a | 5.63                        | 14.68                         | -2.61       | Down    |
| hsa-miR-296-3p               | hsa-mir-296 | 1.35                        | 3.67                          | -2.72       | Down    |
| hsa-miR-29a-5p               | hsa-mir-29a | 2.48                        | 6.54                          | -2.64       | Down    |
| hsa-miR-3130-3p              | hsa-mir-3130-1 | 1.13                        | 4.59                          | -4.06       | Down    |
| hsa-miR-3130-3p              | hsa-mir-3130-2 | 1.13                        | 4.59                          | -4.06       | Down    |
| hsa-miR-3167                 | hsa-mir-3167 | 2.93                        | 6.08                          | -2.08       | Down    |
| hsa-miR-3176                 | hsa-mir-3176 | 9.34                        | 22.94                         | -2.46       | Down    |
| hsa-miR-33b-3p               | hsa-mir-33b | 2.14                        | 4.82                          | -2.25       | Down    |
| hsa-miR-3615                 | hsa-mir-3615 | 4.95                        | 15.71                         | -3.17       | Down    |
| hsa-miR-3619-5p              | hsa-mir-3619 | 1.13                        | 4.01                          | -3.55       | Down    |
Table I. Continued.

| miRNA/miR, microRNA | Precursor | AC16 CMs hypoxia | AC16 CMs normoxia | Fold change | Up/down |
|---------------------|-----------|------------------|------------------|-------------|---------|
| hsa-miR-377-5p      | hsa-mir-377 | 6.53             | 13.30            | -2.04       | Down    |
| hsa-miR-4454        | hsa-mir-4454 | 3.04             | 6.31             | -2.08       | Down    |
| hsa-miR-483-5p      | hsa-mir-483 | 1.69             | 5.05             | -2.99       | Down    |
| hsa-miR-487a-5p     | hsa-mir-487a | 1.35             | 3.10             | -2.30       | Down    |
| hsa-miR-503-5p      | hsa-mir-503 | 4.28             | 10.44            | -2.44       | Down    |
| hsa-miR-541-3p      | hsa-mir-541 | 2.14             | 7.46             | -3.49       | Down    |
| hsa-miR-548d-5p     | hsa-mir-548d-1 | 2.59          | 11.70            | -4.52       | Down    |
| hsa-miR-548d-5p     | hsa-mir-548d-2 | 3.26          | 13.65            | -4.19       | Down    |
| hsa-miR-548n        | hsa-mir-548n | 2.81             | 5.73             | -2.04       | Down    |
| hsa-miR-548o-3p     | hsa-mir-548o | 13.73            | 27.87            | -2.03       | Down    |
| hsa-miR-548o-3p     | hsa-mir-548o-2 | 13.73         | 27.87            | -2.03       | Down    |
| hsa-miR-551b-3p     | hsa-mir-551b | 1.13             | 2.87             | -2.54       | Down    |
| hsa-miR-6840-5p     | hsa-mir-6840 | 1.46             | 2.98             | -2.04       | Down    |
| hsa-miR-6852-5p     | hsa-mir-6852 | 2.03             | 4.36             | -2.15       | Down    |
| hsa-miR-877-5p      | hsa-mir-877 | 9.00             | 18.24            | -2.03       | Down    |
| hsa-miR-887-5p      | hsa-mir-887 | 1.01             | 3.10             | -3.07       | Down    |
| hsa-miR-92a-1-5p    | hsa-mir-92a-1 | 1.35           | 4.01             | -2.97       | Down    |
| hsa-miR-93-3p       | hsa-mir-93 | 1.58             | 7.57             | -4.79       | Down    |

CMs under hypoxia, vs. normoxia. As shown in Fig. 2C and D, 184 miRNAs were identified with >2-fold changes (99 upregulated and 85 downregulated). Following selection of those with thresholds of >1 rpm in both hypoxic and normoxic cells, 62 miRNAs were identified, including 30 miRNAs with >2-fold upregulation and 32 miRNAs with >2-fold downregulation (Table I).

Identification of potential miRNA-mRNA interactions in hypoxic AC16 CMs. The present study aimed to determine the potential miRNA-mRNA interactions in hypoxic AC16 CMs. To achieve this, the putative targets of the miRNAs with >2-fold changes were searched (Fig. 2D) from the NGS results using a miRmap database search for those with threshold miRmap scores >99.0. The genes showing >2-fold changes (Fig. 2B) were matched with these putative targets, and, as shown in the intersection Venn diagram in Fig. 2C, 24 genes were potentially involved in miRNA-mRNA interactions (15 upregulated and nine downregulated) (Table II).

A search was also performed for the potential miRNA-mRNA interactions of the miRNAs with >2-fold changes in various miRNA target predicting databases. On combining the results from miRmap, TargetScan and miRDB, two miRNA-mRNA interactions were identified: hsa-miR-129-5p/CDC42EP3 and hsa-miR-330-3p/HELZ (Fig. 3). However, although hsa-miR-129-5p and hsa-miR-330-3p were significantly upregulated in hypoxic CMs, no significant differences in the expression levels of CDC42EP3 or HELZ were noted between the hypoxic and normoxic CMs.

Validation of the differentially expressed genes in response to hypoxia. The 24 genes with potential miRNA-mRNA interactions (Table II) were further compared against associated array data obtained from the GEO database. Briefly, the gene expression levels in cardiac microvascular endothelial cells were extracted from the GEO database (GEO acces-
GO annotations and KEGG pathway analyses of DEGs in hypoxic AC16 CMs. Network analyses of the 24 genes with potential miRNA-mRNA interactions were performed using IPA software. The top three networks associated with genes targeted by miRNAs differentially expressed in hypoxic AC16 CMs are listed in Table III. In network 1 (Fig. 5A), 14 targeted genes (iodothyronine deiodinase 2, solute carrier family 6 member 13, histone deacetylase 11, STC1, membrane metalloendopeptidase (MME), chac glutathione specific γ-glutamylcyclotransferase 1, iodothyronine deiodinase 2, solute carrier family 7 member 11, Transmembrane protein 144, Histone deacetylase 11) were associated with free radical scavenging, small molecule...
Figure 4. GEO database analysis of genes with potential miRNA-mRNA interactions. The 24 genes with potential miRNA-mRNA interactions, including (A) upregulated and (B) downregulated genes in hypoxic cardiomyocytes are listed in Table II. They were further validated using related array data from the GEO database. The gene expression levels in cardiac microvascular endothelial cells were extracted from the GEO database (GEO accession: GDS3483), and the expression levels of the genes were compared between cells treated with hypoxia for different lengths of time (3, 24 and 48 h) and normoxic cells. *P<0.05; **P<0.01; ***P<0.001. miRNA, microRNA; GEO, Gene Expression Omnibus.
biochemistry, and carbohydrate metabolism. In network 2 (Fig. 5B), seven targeted genes (solute carrier family 7 member 11, activin A receptor like type 1, BNIP3L, MME, METTL7A, TNS1, and G protein-coupled receptor 68) were associated with cancer, organismal injury and abnormalities, and cell death and survival. In network 3, only CAMK1D was associated with carbohydrate metabolism, small molecule biochemistry, and digestive system development and function. Two genes (complement C1q like 1 and transmembrane protein 144) were not involved in these networks.

Functional analysis of the DEGs from mRNA sequencing was also performed by DAVID biological process analysis (Fig. 6). The top four biological processes of these genes were cellular response to hypoxia (12 genes), brown fat cell differentiation (seven genes), positive regulation of apoptotic process (13 genes), and response to hypoxia (nine genes). The protein-coding genes specifically associated with apoptosis, cell proliferation inhibition, and cell cycle arrest were also analyzed with a heatmap (Fig. 7).

The top 20 KEGG pathways of dysregulated genes were identified using mRNA sequencing data (Table IV and Fig. 8). The legionellosis (fold enrichment=7.11), regulation of lipolysis in adipocytes (fold enrichment=6.86), and glycosylation/gluconeogenesis (fold enrichment=5.73) pathways were significantly enriched in the hypoxic CMs.

Discussion

Differential gene expression with altered signaling pathways has been reported in CMs responding to hypoxic/ischemic conditions (3,29,30). The reciprocal regulation of miRNAs and mRNA in human CMs from patients with heart failure has also been investigated using microarray analysis (31). The present study comprehensively surveyed the differential expression of miRNAs and miRNAs and potential mRNA-miRNA interactions using NGS techniques and bioinformatics.

miRNAs are short, small non-coding RNAs, which regulate gene expression via several post-transcriptional processes (32). Hypoxia is a stress condition that may provoke multiple biological and molecular regulatory networks associated with apoptosis, cell proliferation, and alterations in metabolism (32). Previous studies have suggested that miRNAs may potentially be used as novel diagnostic makers and therapeutic targets for hypoxic CMs in clinical scenarios, including AMI (33). The present study found 62 miRNAs with >2-fold changes in hypoxic CMs. Based on the miRNA-miRNA interactions predicted using miRmap, TargetScan and miRDB databases, hsa-miR-129-5p and hsa-miR-330-3p were identified as having the highest potential of becoming such biomarkers.

The overexpression of miR-129-5p inhibits cell proliferation in smooth muscle cells, glioblastoma multiforme cells, gastric cancer cells, and H9C2 CMs (34-37). Previous experimental studies have noted wingless-type MMTV integration site family member 5A, collagen, type I, a1, and cyclin-dependent kinase 6 to be the targets of miR-129-5p (34-37). The overexpression of miR-330 has been found to inhibit cell proliferation through B cell-specific Moloney murine leukemia virus integration site 1, E2F transcription factor 1 and musashi RNA binding protein 1 in osteosarcoma cells, gastric cells, and prostate cancer cells, respectively (38-40). However, miR-330 has also found to increase cell proliferation by regulating SH3-domain GRB2-like 2 and WNT signaling pathways in hypoxia.

Table III. Top three networks associated with genes targeted by microRNAs differentially expressed in hypoxic Ac16 cardiomyocytes.

| Network | Top diseases and functions | Score | Focus molecules | Molecules in network |
|---------|---------------------------|-------|-----------------|---------------------|
| 1       | Free radical scavenging, small molecule biochemistry, carbohydrate metabolism | 32    | 14              | aAPLN, aAPOL6, aBCL2, CAT, aCD4, Cg, aCHAC1, CTPN1, aDIO2, aDMTN, EPAS1, F13A1, FBXO31, G0S2, aHDAC11, aHIF3A, IFNG, IL7RB, LAP3, MAPK1, MICU1, aMME, NFkd kompleks, NRP2, SEC22B, SERPINB8, SLC16A3, aSLC2A5, aSLC6A8, aSTC1, SULF2, aTFRC, TNF, TNFSF4, UTP18 |
| 2       | Cancer, organismal injury and abnormalities, cell death and survival | 13    | 7               | aACVR1B, BMP4, aBNIP3L, C5, CD74, CREBBP, CXCL8, ESRI, F3, FOXO1, GDF2, aGPR68, ID1, Iga, IGFl, Igm, IKBKE, ITGAM, KITLG, aMETTL7A, aMME, MMP14, NCOR2, S100A6, SERPINB5, aSLC7A11, SMAD2, SMARCA2, SMARCA4, SMARCE1, SOX2, STAT3, TLRI, TLRII, aTNS1 |
| 3       | Carbohydrate metabolism, small molecule biochemistry, digestive system development and function | 2     | 1               | aCAMK1D, ERG, GCG, INS |

\(^a\)Focus molecules.
Figure 5. Networks analysis of the 24 differentially expressed genes with potential miRNA-mRNA interactions in hypoxic Ac16 CMs. The network analyses of the 24 differentially expressed genes with potential miRNA-mRNA interactions in hypoxic AC16 CMs were investigated using Ingenuity® Pathway Analysis software. (A) In network 1, 14 targeted genes (DIO2, SLC2A5, APOL6, HDAC11, STC1, MME, CHAC1, APLN, TFRC, CD4, HIF3A, BCL2, DMTN, and SLC6A8) were associated with free radical scavenging, small molecule biochemistry, and carbohydrate metabolism. (B) In network 2, seven targeted genes (SLC7A11, ACVRL1, BNIP3L, MME, METTL7A, TNS1, and GPR68) were associated with cancer, organismal injury and abnormalities, and cell death and survival. In network 3, only CAMKID was associated with carbohydrate metabolism, small molecule biochemistry, and digestive system development and function. CMs, cardiomyocytes; miRNA, microRNA. Diamonds, horizontal ovals, vertical ovals, squares, rectangles, trapezoids, and inverted triangles represent enzymes, transcription regulators, transmembrane receptors, cytokines, ligand-dependent nuclear receptors, transporters, and kinases, respectively. Solid and dashed lines represent direct and indirect action, respectively. Red and green symbols represent upregulated and downregulated molecules, respectively.
human glioblastoma cells and vascular endothelial cells, respectively (41,42). Although the expression levels of these
genes exhibited no significant changes in AC16 CMs exposed to hypoxia, the downstream regulatory mechanisms of
hsa-miR-129-5p and hsa-miR-330-3p in hypoxic CMs warrant further investigation.

The present study identified 24 genes with significant changes and potential miRNA-mRNA interactions. These
genes were associated with important cellular functions, including cell proliferation, apoptosis, and carbohydrate
metabolism. Using the gene expression profiles of cardiac microvascular endothelial cells obtained from the GEO data-
base, it was possible to validate the significant upregulation of TNS1, BNIP3L and STC1, and the significant downregulation
of TFRC and METTL7A in response to hypoxia. CAMK1D exhibited paradoxical changes in different cells.

TNS1 is a focal adhesion molecule which serves as a scaffold for cell mobility and adhesion through binding to
fibronectin and β1-integrin (43,44). The overexpression of TNS1 has been found to contribute to the invasion and metas-
tasis of breast cancer cells (45). TNS1 may also be involved in the micro-environmental changes that occur in the myocar-
dium during hypoxia.

Programmed cell death may occur in CMs via the extrinsic cytokine death pathway or the intrinsic mitochondrial pruning
pathway (46,47). The BNIP3 and BNIP3-like (BNIP3L, also known as NIP3-like protein X, NIP3L, or NIX), belong to the pro-apoptotic Bcl-2 protein family and are mitochondrial stress sensors (48). They can promote mitophagy and autophagy in response to hypoxia (49,50). Upregulated BNIP3 and BNIP3L trigger apoptosis in conditions which include myocardial hypertrophy and are important in cardiac remodelling (51,52).
Therefore, these pathways have been investigated for their potential role in inhibiting ischemic CM apoptosis (53). Similarly, the present study found BNIP3L to be upregulated in hypoxic CMs and cardiac microvascular endothelial cells.

STC1, an endogenous glycoprotein, has anti-inflammatory and anti-oxidative effects through the uncoupling protein (UCP) family in mice kidney and lung injuries (54,55). However, its main role in CMs remains to be elucidated. STC1 has been found to be significantly increased in patients with dilated cardiomyopathy, but normalizes following treatment using a left ventricular assist device (56). STC1 inhibits superoxide generation via the induction of UCP3 in CMs, which may ameliorate angiotensin II-mediated cardiac injury (57). However, the cardiotoxic effects of STC1 also appear to be mediated via mitochondrial injuries through loss of integrity of the mitochondrial membrane, increased mitochondrial calcium levels, and reactive oxygen species production (58).

In the present study, STC1 was upregulated in hypoxic CMs and cardiac microvascular endothelial cells. Whether this upregulation of STC1 was associated with anti-oxidative effects or pro-oxidative effects warrants further investigation.

The present study revealed significant downregulation of TFRC and METTL7A in hypoxic CMs and cardiac microvascular endothelial cells. Previous studies have shown that either iron overloading or deficiency in CMs were associated with cardiotoxicity and heart failure. In mice, the lack of TFRC results in poor cardiac and mitochondrial function, and early death (59). Decreased expression of TFRC has been associated with reduced pulmonary smooth muscle cell proliferation in hypoxia (60). METTL7A has been recognized as a novel tumor suppressor gene (61). The actual role of the downregulation of METTL7A in CMs and cardiac microvascular endothelial cells in response to hypoxia remains uncertain and requires further investigation.

CAMK1D is a key regulator of granulocyte function and has been associated with newly-developed type 2 diabetes mellitus in Japan (62,63). The overexpression of CAMK1D results in increased cell proliferation and epithelial-mesenchymal transition activity in breast epithelial cells (64). In the present study, it was found that CAMK1D was significantly upregulated in hypoxic CMs but significantly downregulated in hypoxic cardiac microvascular endothelial cells. Although the reason for this paradoxical finding remains to be fully elucidated, it was hypothesized that the overexpression of CAMK1D in hypoxic CMs may be involved in alterations in carbohydrate metabolism and cell detachment.

In conclusion, the present study reports on the differentially upregulated/downregulated mRNAs and miRNAs in hypoxic human CMs (Fig. 9). An improved understanding of the mRNA and miRNA profiles, in addition to the potential...
miRNA-mRNA interactions, in hypoxic CMs, enables the development of novel diagnostic tools and therapeutic strategies for hypoxic human CMs as is found in AMI.

Acknowledgements

The authors thank the Center for Research Resources and Development of Kaohsiung Medical University (Kaohsiung, Taiwan).

Funding

The present study was supported by research grants from the Ministry of Science and Technology (grant no. MOST 107-2320-B-037-011-MY3), Kaohsiung Medical University Hospital (grant nos. KMUHSI0701 and KMUHSI0712), and the Kaohsiung Medical University (grant no. KMU-DK108003).

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

HMS and PLK conceived the study. WHL, MJT, WAC, KFC, and PLK analyzed and interpreted the data. LYW and HYW performed the cell culture and flow cytometry. WHL, MJT and PLK were the major contributors in writing the manuscript. WAC produced the illustration. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors confirm that they have no competing interests.

References

1. Lee WH, Hsu PC, Chu CY, Su HM, Lee CS, Yen HW, Lin TH, Voon WC, Lai WT and Sheu SH: Cardiovascular events in patients with atherothrombotic disease: A population-based longitudinal study in Taiwan. PLoS One 9: e92577, 2014.
2. Soler EP and Ruiz VC: Epidemiology and risk factors of cerebral ischemia and ischemic heart diseases: Similarities and differences. Curr Cardiol Rev 6: 138-149, 2010.
6. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Busquets H, Calorio ALF, Crea F, Goodevenus JA, Halvorsen S, et al: 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39: 119-177, 2018.

7. Krijnen PA, Nijmeijer R, Meijer J, Visser A, Hack CE and Niessen HW: Apoptosis in myocardial ischaemia and infarction. J Clin Pathol 55: 801-811, 2002.

8. Takemura G and Fujiiwa H: Morphological aspects of apoptosis in heart disease. Cell Mol Med 10: 56-75, 2006.

9. Breitling-Zoccoli GG, Abbate A, Vastagro F, Scarpa S, Santini D, Leone AM, Parisi Q, De Giorgio F, Bussani R, Silvestri F, et al: Increased apoptosis in remote non-infarcted myocardium in multivessel coronary disease. Int J Cardiol 94: 105-110, 2004.

10. Abbate A, Merli R, Patti G, Balzi D, Dambrosio A, Manzoli A, Balbi A, Fancisco G: Apoptosis in recent myocardial infarction. Clin Ter 151: 247-251, 2000.

11. Saraste A, Kajimura T, Meijer J, Visser A, Hack CE and Niessen HW: Apoptosis in myocardial ischaemia and infarction. J Clin Pathol 55: 801-811, 2002.

12. Takekura G and Fujiiwa H: Morphological aspects of apoptosis in heart disease. Cell Mol Med 10: 56-75, 2006.

13. Breitling-Zoccoli GG, Abbate A, Vastagro F, Scarpa S, Santini D, Leone AM, Parisi Q, De Giorgio F, Bussani R, Silvestri F, et al: Increased apoptosis in remote non-infarcted myocardium in multivessel coronary disease. Int J Cardiol 94: 105-110, 2004.

14. Abbate A, Merli R, Patti G, Balzi D, Dambrosio A, Manzoli A, Balbi A, Fancisco G: Apoptosis in recent myocardial infarction. Clin Ter 151: 247-251, 2000.

15. Saraste A, Pulkki K, Kallajoji M, Henriksen K, Parvinen M, van Dijk E, Auger H, Jaszczyszyn Y and Thermes C: Ten years of next-generation sequencing technology. Trends Genet 30: 418-426, 2014.

16. Mardis ER: Next-generation sequencing platforms. Annu Rev Anal Chem (Palo Alto Calif) 6: 287-303, 2013.

17. Xia P, Liu Y and Cheng Z: Signaling Pathways in Cardiac Myocyte Apoptosis. Biomed Res Int 2016: 9583268, 2016.

18. Chen SC, Chen FW, Hsu YL and Kuo PL: Systematic analysis of transcriptional profile of renal cell carcinoma under long-term hypoxia using next-generation sequencing and bioinformatic. Int J Mol Sci 18, 2017.

19. Blue GM, Kirk EP, Giannoulou E, Dunwoodle SL, Ho JW, Hill DG, Myatt GM, Sholler GF, Harvey RP and Winlaw DS: Targeted next-generation sequencing identifies pathogenic variants in familial congenital heart disease. J Am Coll Cardiol 64: 2498-2506, 2014.

20. Lubitz SA and Ellinor PT: Next-generation sequencing for the diagnosis of cardiac arrhythmia syndromes. Heart Rhythm 12: 1062-1070, 2015.

21. Xia P, Liu Y and Cheng Z: Signaling Pathways in Cardiac Myocyte Apoptosis. Biomed Res Int 2016: 9583268, 2016.

22. Chiong M, Wang ZV, Pedrozo Z, Cao DJ, Troncoso R, Ibacache M, Criollo A, Nemchenko A, Hill JA and Lavandero S: MicroRNA-129-5p inhibits vascular smooth muscle cell proliferation by targeting Wnt5a. Exp Ther Med 14: 2511-2516, 2016.

23. Zeng A, Yin J, Li Y, Li R, Wang Z, Zhou X, Jin X, Shen F, Yan W and You Y: miR-129-5p targets Wnt5a to block PKC/ERK/NF-kappaB and JNK pathways in glioblastoma. Cell Death Dis 9: 391, 2018.

24. Majumdar GD and Raghow R: Trichostatin A induces a unique set of microRNAs including miR-129-5p that blocks cyclin-dependent kinase 6 expression and proliferation in H9c2 cardiac myocytes. Mol Cell Biochem 415: 39-49, 2016.

25. Zheng Z, Bao F, Chen X, Huang H and Zhang X: MicroRNA-330-3p Expression Indicates Good Prognosis and Suppresses Cell Proliferation by Targeting Bmi-1 in Osteosarcoma. Cell Physiol Biochem 46: 442-450, 2016.

26. Guan A, Wang H, Li X, Xie H, Wang R, Zhu Y and Li R: miR-330-3p inhibits gastric cancer cell invasion and proliferation by inhibiting COL1A1. Biochem Cell Biol 96: 19-25, 2018.

27. Zheng Z, Bao F, Chen X, Huang H and Zhang X: MicroRNA-330-3p Expression Indicates Good Prognosis and Suppresses Cell Proliferation by Targeting Bmi-1 in Osteosarcoma. Cell Physiol Biochem 46: 442-450, 2016.

28. Guan A, Wang H, Li X, Xie H, Wang R, Zhu Y and Li R: miR-330-3p inhibits gastric cancer cell invasion and proliferation by inhibiting COL1A1. Biochem Cell Biol 96: 19-25, 2018.

29. Lee KH, Chen YL, Yeh SD, Hsiao M, Lin JT, Goan YG and Lu PJ: MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through EZH2-mediated suppression of Akt phosphorylation. Oncogene 28: 3360-3370, 2009.

30. Qu S, Yao Y, Shang C, Xue Y, Ma J, Li Z and Liu Y: MicroRNA-330 is an oncosuppressor gene in glioblastoma cells by regulating SH3GL2 gene. PLoS One 7: e46010, 2012.

31. Ren J, Ma R, Zhang ZB, Li Y, Lei P and Men JL: Effects of microRNA-330 on vulnerable atherosclerotic plaques formation and vascular endothelial cell proliferation through the WNT signaling pathway in acute coronary syndrome. J Cell Biochem 119: 4514-4521, 2018.

32. Shih YP, Sun P, Wang A and Lo SH: Tensin1 positively regulates RhoA activity through its interaction with DLD1. Biochim Biophys Acta 1835: 3258-3265, 2015.

33. Bernau K, Torr EE, Evans MD, Aoki JK, Ngam CR and Saraste A: Tensin 1 is essential for myoblast differentiation and extracellular matrix formation. Am J Respir Cell Mol Biol 56: 465-476, 2017.
45. Zhan Y, Liang X, Li L, Wang B, Ding F, Li Y, Wang X, Zhan Q and Liu Z: MicroRNA-548j functions as a metastasis promoter in human breast cancer by targeting Tensin1. Mol Oncol 10: 838-849, 2016.

46. Dorn GW II: Mitochondrial pruning by Nix and BNip3: An essential function for cardiocyte-expressed death factors. J Cardiovasc Transl Res 3: 374-383, 2010.

47. Ney PA: Mitochondrial autophagy: Origins, significance, and role of BNIP3 and NIX. Biochim Biophys Acta 1853: 2775-2783, 2015.

48. Chinnadurai G, Vijayalingam S and Gibson SB: BNIP3 subfamily BH3-only proteins: Mitochondrial stress sensors in normal and pathological functions. Oncogene 27 (Suppl 1): S114-S127, 2008.

49. O'Sullivan TE, Johnson LR, Kang HH and Sun JC: BNIP3- and BNIP3L-mediated mitophagy promotes the generation of natural killer cell memory. Immunity 43: 331-342, 2015.

50. Mazure NM and Pouyssegur J: Atypical BH3-domains of BNIP3 and BNIP3L lead to autophagy in hypoxia. Autophagy 5: 868-869, 2009.

51. Yussman MG, Toyokawa T, Odley A, Lynch RA, Wu G, Colbert Mc, Aronow BJ, Lorenz JN and Dorn GW II: Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. Nat Med 8: 725-730, 2002.

52. Dorn GW II and Kirshenbaum LA: Cardiac reanimation: Targeting cardiomyocyte death by BNIP3 and NIX/BNIP3L. Oncogene 27 (Suppl 1): S158-S167, 2008.

53. Diwan A, Krenz M, Syed FM, Wansapura J, Ren X, Koesters AG, Li H, Kirshenbaum LA, Hahn HS, Robbins J, et al: Inhibition of ischemic cardiomyocyte apoptosis through targeted ablation of BNip3 restrains postinfarction remodeling in mice. J Clin Investig 117: 2825-2833, 2007.

54. Pan JS, Huang L, Belousova T, Lu L, Yang Y, Reddel R, Chang A, Ju H, DiMattia G, Tong Q and Sheikh-Hamad D: Stanniocalcin-1 inhibits renal ischemia/reperfusion injury via an AMP-activated protein kinase-dependent pathway. J Am Soc Nephrol 26: 364-378, 2015.

55. Tang SE, Wu CP, Wu SY, Peng CK, Perng WC, Kang BH, Chu SJ and Huang KL: Stanniocalcin-1 ameliorates lipopolysaccharide-induced pulmonary oxidative stress, inflammation, and apoptosis in mice. Free Radic Biol Med 71: 321-331, 2014.

56. Sheikh-Hamad D, Bick R, Wu GY, Christensen BM, Razeghi P, Poinxeter B, Taegehmeyer H, Wamsley A, Padda R, Entman M, et al: Stanniocalcin-1 is a naturally occurring L-channel inhibitor in cardiomyocytes: Relevance to human heart failure. Am J Physiol Heart Circ Physiol 285: H442-H448, 2003.